We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Evotec Announce Preliminary Findings of its Orally Active NR2B Subtype Selective NMDA Receptor Antagonist

News   Apr 02, 2008

 
Evotec Announce Preliminary Findings of its Orally Active NR2B Subtype Selective NMDA Receptor Antagonist
 
 
 

RELATED ARTICLES

Cobra Biologics, GE Healthcare and Centre for Process Innovation Collaborate to Advance Gene Therapy

News

Innovate UK funded project supports development of scalable, cost effective production of regenerative medicines.

READ MORE

Existing Drug Could Treat Porphyria

News

An existing antifungal drug, ciclopirox (CPX), has been shown to improve symptoms associated with congenital erythropoietic porphyria – the rarest type of porphyria.

READ MORE

Better Tailored Drugs with Fewer Side-Effects

News

A recent achievement in the field of protein research allows for better tailored pharmaceuticals with fewer side-effects.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE